ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Tru T calculator - what is the range?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 154209" data-attributes="member: 13851"><p><strong>"Based on the <span style="color: rgb(44, 130, 201)">new data on the distribution of free testosterone levels in healthy men </span>the target range of free testosterone has been determined to be <span style="color: rgb(184, 49, 47)">164 to 314 pg/ml </span>(<span style="color: rgb(184, 49, 47)">mean+/−1SD</span>)"</strong></p><p></p><p></p><p>.....which would convert to <strong><span style="color: rgb(184, 49, 47)">16-31 ng/dl</span></strong></p><p></p><p></p><p></p><p></p><p></p><p></p><p><span style="color: rgb(44, 130, 201)"><strong>*</strong>highlighted in blue- <strong>refer to the new Multi-step Dynamic Binding Model with Complex Allostery (TruT calculated)</strong> </span></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(251, 160, 38)">In one aspect, described herein is a computer implemented method for determining a need for adjustment of a dose of testosterone administered to an individual with hypogonadism, androgen deficiency syndrome, or any other condition for which testosterone therapy is indicated, comprising: on a device having one or more processors and a memory storing one or more programs for execution by the one or more processors, the one or more programs including instructions for:</span></strong> <strong><span style="color: rgb(0, 0, 0)">a) receiving data from determining the concentration of free testosterone in an individual receiving testosterone therapy at a first dose, wherein the concentration of free testosterone is determined by measuring</span></strong> <span style="color: rgb(184, 49, 47)"><strong>i) a total SHBG concentration,</strong></span><span style="color: rgb(26, 188, 156)"> <strong>ii) a total testosterone concentration,</strong></span> <strong><span style="color: rgb(147, 101, 184)">and iii) a total albumin concentration</span></strong> <span style="color: rgb(0, 0, 0)"><strong>in a biological sample obtained from an individual, to determine free testosterone concentration from the individual;</strong></span> <span style="color: rgb(44, 130, 201)"><strong>b) attributing at least two distinct interconverting microstates of an unliganded SHBG dimer having a first monomer and a second monomer by applying the New Multi-Step Dynamic Binding Model with Complex Allostery to the data of step a);</strong></span> <span style="color: rgb(184, 49, 47)"><strong>c) calculating the free testosterone concentration in the individual using </strong></span><strong><span style="color: rgb(44, 130, 201)">the New Multi-step Dynamic Binding Model with Complex Allostery encompassing readjustment of a first equilibria between the microstates upon binding of a first testosterone molecule to the first monomer and an allosteric interaction between two binding sites of the SHBG dimer and; </span>d) sending a signal for providing a second (adjusted) dose of testosterone that is higher than the first dose when <span style="color: rgb(184, 49, 47)">the</span> <span style="color: rgb(184, 49, 47)">free testosterone concentration is below the lower end of the target therapeutic range </span>(e.g. <span style="color: rgb(184, 49, 47)">164 pg/ml</span>);</strong> <strong>and e) sending a signal for providing a second (adjusted) dose of testosterone that is lower than the first dose when <span style="color: rgb(184, 49, 47)">the free testosterone concentration is above the upper end of the target therapeutic range </span>(e.g. <span style="color: rgb(184, 49, 47)">314 pg/ml</span>). </strong>In some embodiments, the system can further comprise the step of receiving data of the first dose of testosterone administered to the individual.</p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(44, 130, 201)">Formulas described herein relate to a model of testosterone and SHBG binding in which two distinct interconverting microstates of an unliganded SHBG dimer having a first monomer and a second monomer. SHBG exists as one of two dimerized forms or microstates (see, e.g., FIG. 3), </span><span style="color: rgb(251, 160, 38)">each of which can bind to a first testosterone molecule with a different affinity. </span><span style="color: rgb(184, 49, 47)">These two microstates of SHBG can interconvert. </span><span style="color: rgb(44, 130, 201)">The new Multi-step Dynamic Binding Model with Complex Allostery described herein is a model of the interaction between testosterone and SHBG which accounts for both a first equilibria between the microstates upon binding of a first testosterone molecule to the first monomer and an allosteric interaction between two binding sites of the SHBG dimer.</span></strong></p><p></p><p></p><p></p><p></p><p></p><p><strong>Using the methods, assays, and systems described herein, <span style="color: rgb(184, 49, 47)">the optimal range of free testosterone concentrations that should be targeted in hypogonadal men receiving testosterone replacement therapy have also been determined.</span> The treatment of hypogonadism with testosterone is currently suboptimal. The analyses of clinical trials data described herein demonstrate that a large fraction of hypogonadal men treated with testosterone therapy have testosterone levels in the subtherapeutic range. </strong></p><p></p><p></p><p><strong>The current Endocrine Society guidelines suggest the use of total testosterone levels to guide therapy, which as discussed above, do not provide an accurate assessment of the androgen status. <span style="color: rgb(184, 49, 47)">The free testosterone concentrations, </span><span style="color: rgb(44, 130, 201)">determined the new method described herein,</span><span style="color: rgb(184, 49, 47)"> can provide accurate assessment of the adequacy of testosterone therapy in hypogonadal men.</span> <span style="color: rgb(44, 130, 201)">Based on the new data on the distribution of free testosterone levels in healthy men the target range of free testosterone has been determined to be </span><span style="color: rgb(184, 49, 47)">164 to 314 pg/ml </span><span style="color: rgb(44, 130, 201)">(</span><span style="color: rgb(184, 49, 47)">mean+/−1SD</span><span style="color: rgb(44, 130, 201)">). </span>If the on-treatment free testosterone concentrations <span style="color: rgb(44, 130, 201)">determined using the methods described herein</span> are outside this range, the dose of testosterone should be adjusted <span style="color: rgb(44, 130, 201)">using the methods described herein</span> to achieve testosterone levels in the target therapeutic range to maximize benefits and reduce the risks. Furthermore, the initial dose of testosterone therapy can be determined using the methods, assays, and/or systems described herein, e.g. the dosimeter methods described herein. </strong></p></blockquote><p></p>
[QUOTE="madman, post: 154209, member: 13851"] [B]"Based on the [COLOR=rgb(44, 130, 201)]new data on the distribution of free testosterone levels in healthy men [/COLOR]the target range of free testosterone has been determined to be [COLOR=rgb(184, 49, 47)]164 to 314 pg/ml [/COLOR]([COLOR=rgb(184, 49, 47)]mean+/−1SD[/COLOR])"[/B] .....which would convert to [B][COLOR=rgb(184, 49, 47)]16-31 ng/dl[/COLOR][/B] [COLOR=rgb(44, 130, 201)][B]*[/B]highlighted in blue- [B]refer to the new Multi-step Dynamic Binding Model with Complex Allostery (TruT calculated)[/B] [/COLOR] [B][COLOR=rgb(251, 160, 38)]In one aspect, described herein is a computer implemented method for determining a need for adjustment of a dose of testosterone administered to an individual with hypogonadism, androgen deficiency syndrome, or any other condition for which testosterone therapy is indicated, comprising: on a device having one or more processors and a memory storing one or more programs for execution by the one or more processors, the one or more programs including instructions for:[/COLOR][/B] [B][COLOR=rgb(0, 0, 0)]a) receiving data from determining the concentration of free testosterone in an individual receiving testosterone therapy at a first dose, wherein the concentration of free testosterone is determined by measuring[/COLOR][/B] [COLOR=rgb(184, 49, 47)][B]i) a total SHBG concentration,[/B][/COLOR][COLOR=rgb(26, 188, 156)] [B]ii) a total testosterone concentration,[/B][/COLOR] [B][COLOR=rgb(147, 101, 184)]and iii) a total albumin concentration[/COLOR][/B] [COLOR=rgb(0, 0, 0)][B]in a biological sample obtained from an individual, to determine free testosterone concentration from the individual;[/B][/COLOR] [COLOR=rgb(44, 130, 201)][B]b) attributing at least two distinct interconverting microstates of an unliganded SHBG dimer having a first monomer and a second monomer by applying the New Multi-Step Dynamic Binding Model with Complex Allostery to the data of step a);[/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]c) calculating the free testosterone concentration in the individual using [/B][/COLOR][B][COLOR=rgb(44, 130, 201)]the New Multi-step Dynamic Binding Model with Complex Allostery encompassing readjustment of a first equilibria between the microstates upon binding of a first testosterone molecule to the first monomer and an allosteric interaction between two binding sites of the SHBG dimer and; [/COLOR]d) sending a signal for providing a second (adjusted) dose of testosterone that is higher than the first dose when [COLOR=rgb(184, 49, 47)]the[/COLOR] [COLOR=rgb(184, 49, 47)]free testosterone concentration is below the lower end of the target therapeutic range [/COLOR](e.g. [COLOR=rgb(184, 49, 47)]164 pg/ml[/COLOR]);[/B] [B]and e) sending a signal for providing a second (adjusted) dose of testosterone that is lower than the first dose when [COLOR=rgb(184, 49, 47)]the free testosterone concentration is above the upper end of the target therapeutic range [/COLOR](e.g. [COLOR=rgb(184, 49, 47)]314 pg/ml[/COLOR]). [/B]In some embodiments, the system can further comprise the step of receiving data of the first dose of testosterone administered to the individual. [B][COLOR=rgb(44, 130, 201)]Formulas described herein relate to a model of testosterone and SHBG binding in which two distinct interconverting microstates of an unliganded SHBG dimer having a first monomer and a second monomer. SHBG exists as one of two dimerized forms or microstates (see, e.g., FIG. 3), [/COLOR][COLOR=rgb(251, 160, 38)]each of which can bind to a first testosterone molecule with a different affinity. [/COLOR][COLOR=rgb(184, 49, 47)]These two microstates of SHBG can interconvert. [/COLOR][COLOR=rgb(44, 130, 201)]The new Multi-step Dynamic Binding Model with Complex Allostery described herein is a model of the interaction between testosterone and SHBG which accounts for both a first equilibria between the microstates upon binding of a first testosterone molecule to the first monomer and an allosteric interaction between two binding sites of the SHBG dimer.[/COLOR][/B] [B]Using the methods, assays, and systems described herein, [COLOR=rgb(184, 49, 47)]the optimal range of free testosterone concentrations that should be targeted in hypogonadal men receiving testosterone replacement therapy have also been determined.[/COLOR] The treatment of hypogonadism with testosterone is currently suboptimal. The analyses of clinical trials data described herein demonstrate that a large fraction of hypogonadal men treated with testosterone therapy have testosterone levels in the subtherapeutic range. [/B] [B]The current Endocrine Society guidelines suggest the use of total testosterone levels to guide therapy, which as discussed above, do not provide an accurate assessment of the androgen status. [COLOR=rgb(184, 49, 47)]The free testosterone concentrations, [/COLOR][COLOR=rgb(44, 130, 201)]determined the new method described herein,[/COLOR][COLOR=rgb(184, 49, 47)] can provide accurate assessment of the adequacy of testosterone therapy in hypogonadal men.[/COLOR] [COLOR=rgb(44, 130, 201)]Based on the new data on the distribution of free testosterone levels in healthy men the target range of free testosterone has been determined to be [/COLOR][COLOR=rgb(184, 49, 47)]164 to 314 pg/ml [/COLOR][COLOR=rgb(44, 130, 201)]([/COLOR][COLOR=rgb(184, 49, 47)]mean+/−1SD[/COLOR][COLOR=rgb(44, 130, 201)]). [/COLOR]If the on-treatment free testosterone concentrations [COLOR=rgb(44, 130, 201)]determined using the methods described herein[/COLOR] are outside this range, the dose of testosterone should be adjusted [COLOR=rgb(44, 130, 201)]using the methods described herein[/COLOR] to achieve testosterone levels in the target therapeutic range to maximize benefits and reduce the risks. Furthermore, the initial dose of testosterone therapy can be determined using the methods, assays, and/or systems described herein, e.g. the dosimeter methods described herein. [/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Tru T calculator - what is the range?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top